The prespecified baseline characteristics of the RECOURSE trial were well balanced between the FTD/TPI and placebo arms in KRASG12 mutant, KRASG13 mutant and KRASWT subgroups (Table 2), with some exceptions; patients whose tumors harbored a KRAS mutation generally had more recent diagnoses of metastatic disease, were less heavily pretreated and were more frequently refractory to fluoropyrimidine as part of the last previous regimen (Table 2). The gene discussed is KRAS; the disease is metastatic neoplasm.